Elderly people (age 65 years and older) are the most rapidly growing segment of the US population and the incidence of epilepsy is greatest in this age group. Little information is available about the use or outcomes associated with antiepileptic drugs (AEDs) by these vulnerable persons. We will examine pattems of AED use and associated outcomes among nursing home (NH) and community based elderly. For the proposed research, we have available two large electronic data sets: (1) the Beverly Enterprises Inc. centralized records (the Minimum Data Set and physicians' orders) for two calendar years (1999, 2000) for all residents (N~140,000 for two years) living in 501 NHs in 31 states, and (2) the Health Care Financing Administration's (HCFA) integration of the Medicare Current Beneficiaries Survey with Medicare claims files (N~12,000 elderly per year) for 7 calendar years. Both of these data sets have been used in part during the current project (1997-2002) by the same multidisciplinary team that will be working in the proposed project. We have a thorough working knowledge of the complexities of these data sets and the richness of information they contain. In our current research, we found a prevalence of 7.7% for AED use by NH admissions. Significant covadates with AED use at admission were epilepsy/seizure, bipolar depression, age group, and cognitive performance. During the first 3 months following admission, an additional 2.7% people were initiated on AEDs. Epilepsy/seizure indication was present in 5.8% of all admissions and an additional 1.47% of the follow-up cohort during the first 3 months.
Specific aims of the proposed project are: (1) outcomes associated with any AED use by eldedy, (2) pharmacoepidemiology, characteristics, and outcomes associated with CBZ, PHT and VPA, and (3) the pharmacoepidemiology of other specific AEDs. Patient outcomes will be captured through incidence events, while AED use can be tracked continuously over time. Multivariate-modeling techniques will be used, controlling for demographics, co-morbidities, and regional effects. Other P50 teams are studying the elimination kinetics of AEDs, and we will use this knowledge to develop age, gender and co-medication specific estimated total and unbound concentrations for NH residents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS016308-22A1
Application #
6666467
Study Section
Project Start
2002-09-30
Project End
2003-08-31
Budget Start
Budget End
Support Year
22
Fiscal Year
2002
Total Cost
$297,610
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Conway, Jeannine M; Eberly, Lynn E; Collins, Joseph F et al. (2017) Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy. Pharmacotherapy 37:1197-1203
Polepally, Akshanth R; Remmel, Rory P; Brundage, Richard C et al. (2015) Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. J Clin Pharmacol 55:1101-8
Patel, Sima I; Birnbaum, Angela K; Cloyd, James C et al. (2015) Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy. CNS Drugs 29:1009-22
Conway, Jeannine M; Birnbaum, Angela K; Leppik, Ilo E et al. (2014) Safety of an intravenous formulation of lamotrigine. Seizure 23:390-2
Ghodke-Puranik, Yogita; Thorn, Caroline F; Lamba, Jatinder K et al. (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23:236-41
Ahmed, Ghada F; Brundage, Richard C; Marino, Susan E et al. (2013) Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol 53:276-84
Puranik, Yogita Ghodke; Birnbaum, Angela K; Marino, Susan E et al. (2013) Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14:35-45
Conway, Jeannine M; Birnbaum, Angela K; Marino, Susan E et al. (2012) A sensitive capillary GC-MS method for analysis of topiramate from plasma obtained from single-dose studies. Biomed Chromatogr 26:1071-6
Punyawudho, Baralee; Ramsay, Eugene R; Brundage, Richard C et al. (2012) Population pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit 34:176-81
Marino, S E; Birnbaum, A K; Leppik, I E et al. (2012) Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther 91:483-8

Showing the most recent 10 out of 96 publications